COVID-19-Associated Disease Course Is Shortened in Moderate-to-Severe Atopic Dermatitis Patients Receiving Dupilumab Treatment: A Retrospective Cross-Sectional Study

Previous studies suggest that allergic diseases may be a protective factor in SARS-CoV-2 infection. However, data regarding the impact of dupilumab, a widely used immunomodulatory medication, on COVID-19 in an allergic population are very limited. To investigate the incidence and severity of COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Dongxia, Wang, Yin, Huang, Nan, Li, Wenjing, Chen, Hao, Yang, Yaqi, Zhu, Rongfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219280/
https://www.ncbi.nlm.nih.gov/pubmed/37240520
http://dx.doi.org/10.3390/jcm12103415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219280/
https://www.ncbi.nlm.nih.gov/pubmed/37240520
http://dx.doi.org/10.3390/jcm12103415

Ejemplares similares